-
- Kajiura T
- Department of Internal Medicine, Kansai Medical University
-
- Isami Y
- Department of Internal Medicine, Kansai Medical University
-
- Katsura K
- Department of Internal Medicine, Kansai Medical University
-
- N Inami
- Department of Internal Medicine, Kansai Medical University
-
- Kanazawa S
- Department of Internal Medicine, Kansai Medical University
-
- Yamada K
- Department of Internal Medicine, Kansai Medical University
-
- Kitano T
- Department of Internal Medicine, Kansai Medical University
-
- Okamoto M
- Department of Internal Medicine, Kansai Medical University
-
- Muramatsu M
- Department of Internal Medicine, Kansai Medical University
-
- Ono T
- Department of Internal Medicine, Kansai Medical University
-
- Omiya M
- Department of Internal Medicine, Kansai Medical University
-
- Tagawa Y
- Department of Internal Medicine, Kansai Medical University
-
- Takaoka M
- Department of Internal Medicine, Kansai Medical University
-
- Fujii T
- Department of Internal Medicine, Kansai Medical University
-
- Nakamori H
- Department of Internal Medicine, Kansai Medical University
-
- N Takahashi
- Department of Internal Medicine, Kansai Medical University
-
- Fujimoto M
- Department of Internal Medicine, Kansai Medical University
-
- Tsuda N
- Department of Internal Medicine, Kansai Medical University
Search this article
Description
Considering that dialysis patients are often elderly, the onset risk of gastric mucosa disorder is increased in them. Therefore, the use of a selective cyclooxigenase (COX)-2 inhibitor that is expected to reduce the digestive disorders in the dialysis patients is of great significance. We investigated pharmacokinetics of meloxicam which is a selective COX-2 inhibitor approved in over 100 countries including Japan. Nine renal patients (4 males and 5 females) on hemodialysis were investigated. Single oral administration of meloxicam was conducted after supper the day before dialysis and plasma consentration was determined. The blood was taken at 1 hour, before start of dialysis. The meloxicam concentratio n was analysed by ultrafiltration. The mean plasma meloxicam concentration (meant-SD) at 1 hour before start of dialysis and at 1,4 and 48 hours after the start of dialysis were 541±168 ng/ml,532±153,512± 161,42± 72, respectively. The re sults indicated not significant changes in the plasma concentration at 1 and 4 hours after start of dialysis.
Journal
-
- The Journal of Kansai Medical University
-
The Journal of Kansai Medical University 56 (2-4), 169-171, 2004
The Medical Society of Kansai Medical University
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680435194752
-
- NII Article ID
- 130004625727
- 110004737295
-
- NII Book ID
- AN00046712
-
- NDL BIB ID
- 7742784
-
- ISSN
- 00228400
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed